194 related articles for article (PubMed ID: 6740497)
1. Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up.
Hubay CA; Gordon NH; Crowe JP; Guyton SP; Pearson OH; Marshall JS; Mansour EG; Hermann RE; Jones JC; Flynn WJ
Surgery; 1984 Jul; 96(1):61-72. PubMed ID: 6740497
[TBL] [Abstract][Full Text] [Related]
2. Assessment of tamoxifen as adjuvant therapy in stage II breast cancer: a long-term follow-up.
Marshall JS; Gordon NH; Hubay CA; Pearson OH
J Lab Clin Med; 1987 Mar; 109(3):300-7. PubMed ID: 3819572
[TBL] [Abstract][Full Text] [Related]
3. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
Gordon NH; Silverman P; Lasheen W; Meinert J; Siminoff LA
Breast Cancer Res Treat; 2007 May; 102(3):301-12. PubMed ID: 17033926
[TBL] [Abstract][Full Text] [Related]
4. Short-term tamoxifen plus chemotherapy: superior results in node-positive breast cancer.
Crowe JP; Gordon NH; Shenk RR; Soegiarso RW; Hubay CA; Mansour EG; Shuck JM; Pearson OH; Marshall JS; Arafah B
Surgery; 1990 Oct; 108(4):619-27; discussion 627-8. PubMed ID: 2218871
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
6. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
7. Antiestrogen, cytotoxic chemotherapy, and bacillus Calmette-Guerin vaccination in stage II breast cancer: a preliminary report.
Hubay CA; Pearson OH; Marshall JS; Rhodes RS; Debanne SM; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C; McGuire WL
Surgery; 1980 May; 87(5):494-501. PubMed ID: 7368100
[TBL] [Abstract][Full Text] [Related]
8. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year results.
Pearson OH; Hubay CA; Marshall JS; Gordon NH; McGuire WL; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C
Breast Cancer Res Treat; 1983; 3 Suppl():S61-8. PubMed ID: 6367862
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant systemic therapy in primary breast cancer.
Mouridsen HT; Palshof T
Acta Chir Scand Suppl; 1984; 519():43-53. PubMed ID: 6393664
[No Abstract] [Full Text] [Related]
11. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
12. [Prospective randomized trial on the efficacy of adjuvant endocrine therapy for ER-positive breast cancer patients after radical mastectomy].
Jiang Z; Song S; Liu X
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):420-2. PubMed ID: 11810777
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6-year result.
Hubay CA; Pearson OH; Manni A; Gordon NH; McGuire WL
J Steroid Biochem; 1985 Dec; 23(6B):1147-50. PubMed ID: 3912620
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant tamoxifen versus tamoxifen plus CMF in the treatment of early breast cancer in Greece. Fifteen-year results of a randomised prospective trial and the potential risks of the antioestrogen.
Vorgias G; Koukouras D; Tzoracoeleftherakis E; Paleogianni V; Androulakis J
Anticancer Res; 2000; 20(5C):3849-54. PubMed ID: 11268466
[TBL] [Abstract][Full Text] [Related]
15. Recurrence patterns in a prospective study of patients with stage II breast cancer treated with endocrine-chemotherapy.
Crowe JP; Gordon NH; Antunez AR; Hubay CA; Pearson OH; Marshall JS; McGuire WL
Surgery; 1987 Oct; 102(4):622-7. PubMed ID: 3310297
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant systemic treatment of resectable breast cancer: eleven years results of a monoinstitutional chemo-hormone-immunotherapy trial.
Rosso R; Boccardo F; Brema F; Sertoli MR; Amoroso D; Bertelli G; Pronzato P
Anticancer Res; 1989; 9(4):1153-6. PubMed ID: 2817796
[TBL] [Abstract][Full Text] [Related]
17. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
18. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
[TBL] [Abstract][Full Text] [Related]
19. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
Schmid P; Untch M; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Lehmann U; Maubach L; Meurer J; Wallwiener D; Possinger K
J Clin Oncol; 2007 Jun; 25(18):2509-15. PubMed ID: 17577027
[TBL] [Abstract][Full Text] [Related]
20. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]